BioSpace News Archive

Small business, Evon Medics, LLC today announced that community engagement and social work consultant, Mr. George C. McFarland has joined the advisory board of the company in a formal advisory role.

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the appointment of two highly experienced leaders, Julie Clark, M.D., as chief medical officer, and Brigit Riley, Ph.D., as chief scientific officer effective immediately, both reporting directly to Laurent Fischer, M.D., Adverum’s chief executive officer.

Palmetto GBA, Administrator of Medicare in Seven States, Publishes Draft Local Coverage Determination

Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today the publication of an article in the journal Nature Communications by Surrozen scientists, demonstrating the effects of selective bispecific Wnt mimetics for bone loss and repair in disease models of osteoporosis, aging and long-bone fracture.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 2,893,962 covering AllocetraTM, the Company’s immunotherapy product candidate.

Sanofi provides update on venglustat clinical program P ARIS – JUNE 1 , 20 21 – A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD. The safety profile of venglustat remains consistent with previously reported results with more than 500 patients treated to date over a period of up to four years across all clinical programs. Biomarker data from th

AB Science SA announced that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide.

Conference call to discuss these results and the COVID-19 treatment landscape with 3 renowned scientific experts on June 10 at 8am ET/2pm CET

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ ® versus Natural History in Frontiers in Neurology Clinically meaningful difference between visual outcomes of LUMEVOQ ® -treated patients and untreated patients